Exclusive Nicholas Florko Warren, Grassley threaten to slap FDA with a 30-day deadline for OTC hearing aid rules
First Opinion John N. Mafi and Catherine Sarkisian Medicare got it right: Unproven Alzheimer’s drug would have threatened the financial stability of 60 million Americans
Politics Rachel Cohrs Medicare finalizes its restrictions on new Alzheimer’s drug, despite pressure from drugmakers
Pharmalot Ed Silverman Many Medicare Part D beneficiaries don’t fill prescriptions for high-priced medicines
First Opinion David C. Grabowski, Marilyn Rantz and Jasmine L. Travers Report: U.S. nursing home care is ineffective, inefficient, inequitable, fragmented, and unsustainable
D.C. Diagnosis Nicholas Florko Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy
First Opinion Constantinos Michaelidis and Candra Szymanski Home care instead of hospital care: Congress should extend a crucial waiver
Insurance Bob Herman Biden administration funnels one of the largest-ever pay increases to Medicare Advantage insurers
Insurance Bob Herman and Tara Bannow UnitedHealth’s deal with LHC highlights broader interest in home health industry
First Opinion Amol Navathe, Risa Lavizzo-Mourey and Joshua Liao How to fix the two-tier U.S. health payment system
Politics Rachel Cohrs Medicare premiums could decrease ‘soon,’ after decision on Alzheimer’s drug Aduhelm
D.C. Diagnosis Nicholas Florko Inside the push for a permanent pandemic preparedness office at the White House
First Opinion Ge Bai and David A. Hyman Nonprofit hospitals’ community benefits should square with their tax exemptions. They often don’t
Biotech Nicholas Florko Biogen pushes back on Medicare’s limits on Alzheimer’s drug coverage — and advances a counteroffer
Politics Nicholas Florko The unexpected forces behind thousands of comments about Medicare’s limits on a new Alzheimer’s drug
First Opinion Linda H. Aiken and Claire M. Fagin Medicare can help fix the nurse shortage in hospitals
First Opinion Caroline Behr and Michael L. Barnett High-risk individuals should get priority access to Covid therapies. That isn’t happening
Exclusive Damian Garde and Adam Feuerstein With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions
Health Nicholas Florko With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment
Politics Rachel Cohrs Medicare plans to restrict access to controversial, pricey Alzheimer’s drug Aduhelm to patients in clinical trials
Politics Rachel Cohrs Becerra orders Medicare to reconsider premium hike following price drop for Biogen’s Aduhelm
Pharmalot Ed Silverman A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs
Pharmalot Rachel Cohrs and Ed Silverman Biden administration poised to give pharmacies a major lobbying win
First Opinion Reshma Ramachandran, Tianna Zhou and Joseph S. Ross Out-of-pocket drug costs for Medicare beneficiaries need to be reined in
First Opinion Sterling N. Ransone, Jr. Clinical labor pricing updates are needed to address workforce shortages, financial strain